Stabilization of kidney function and reduction in heart failure events with sodium‐glucose co‐transporter 2 inhibitors: A meta‐analysis and meta‐regression analysis
Pooled result · Composite of HF hospitalization or cardiovascular deathResult — go to the resultHazard ratio 0.77 95% CI 0.74–0.81Authors' conclusion
Improvement in chronic eGFR slope, which reflects the stabilization of kidney function, is significantly associated with the efficacy of the SGLT2 inhibitor in HF, highlighting the cardiorenal axis role in the beneficial effects on HF. The chronic eGFR slope can be a surrogate marker of the effects of SGLT2 inhibitors on HF reduction.
Study context
- Population
- Participants with or without T2D in randomized placebo-controlled trials of SGLT2i reporting heart failure (HF) hospitalization or CV death, published until 28 February 2023
- Participants
- 90,413 participants13 trials
- Comparison
- SGLT2i vs placebo
- Outcome
- Composite of:
- HF hospitalization
- Cardiovascular death
Methodological detailsrandom-effects meta-analysis, mixed-effects meta-regression, placebo-controlled trials
- Random-effects meta-analysis
- Mixed-effects meta-regression
- Placebo-controlled trials
Pooled result
As reported in the abstract
Hazard ratio
0.77
95% CI 0.74–0.81
P < 0.0001
SGLT2 inhibitorsvs Placebo
HR 0.77 (95% CI 0.74–0.81); P < 0.0001
Further pooled results
Meta-regression: chronic estimated glomerular filtration rate (eGFR) slope (eGFR change after initial dip) and composite outcome
- Chronic eGFR slope significantly associated with composite outcome
- P = 0.017
- Reduction in composite outcome per 1 ml/min/1.73 m² /year improvement in chronic eGFR slope
- 14%
Meta-regression: changes in HbA1c, body weight, systolic BP, haematocrit, overall eGFR slope
- Changes in the other parameters showed no significant associations
Original publication
Stabilization of kidney function and reduction in heart failure events with sodium‐glucose co‐transporter 2 inhibitors: A meta‐analysis and meta‐regression analysis. Diabetes Obes Metab. Published 22 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →